Practical implementation of automated large-scale iPS cell passaging
First written in FY2018. 5 of 7 entries say "Advanced", first in FY2019. Latest entry: FY2026.
1 other company's latest entry also says "Restated".
- FY2026RestatedAnnual report
「We are continuing PR activities and full-scale sales of MakCell® (the successor to the CellPet® series of automated cell culture systems for iPS cells) in related markets including pharmaceuticals and drug discovery, and have begun exploring new markets such as food and cosmetics.」
The company is continuing full-scale sales of MakCell and exploring new markets, including food and cosmetics. - FY2024AdvancedAnnual report
「We succeeded in developing MakCell® for volume production and have begun full-scale sales.」
MakCell successfully completed volume-production development and progressed to the full-scale sales stage. - FY2022AdvancedAnnual report
「We conducted volume-production development of MakCell® (the successor to the CellPet® series of automated cell culture systems for iPS cells).」
The development of MakCell for volume production of an automated cell culture system for iPS cells progressed to the implementation stage. - FY2020AdvancedAnnual report
「During the fiscal year, we launched the KB2000 automated cell culture system.」
Regarding the practical application of automated cell culture systems, the KB2000 was launched. The company also described the development of MakCell and a new research grant project concerning technology for dispersing large cell aggregates, including those of iPS cells. - FY2020-Q2AdvancedAnnual report
「Sales of the KB2000 automated cell culture system for iPS cells began, while revenue from commissioned R&D in the regenerative medicine field also drove performance.」
Sales of the KB2000 automated cell culture system for iPS cells began, advancing the practical application of automated large-scale passaging culture to the product sales stage. - FY2019AdvancedAnnual report
「During the fiscal year, the Company completed an automated system for large-scale passaging culture of iPS cells. In the following fiscal year, it plans to install the system at the Faculty of Medicine, Osaka University, and conduct field testing.」
The low-cost automated system for large-scale passaging culture, meeting requirements for quality, variability and cost, has been completed, and introduction and field testing at the Osaka University Faculty of Medicine are planned for the following fiscal year. - FY2018First statedAnnual report
「Accordingly, in this study we aim to build a low-cost automated system for large-scale passaging culture that can be readily adopted in clinical settings and to provide cells meeting requirements for quality, variability and cost.」
As an FY2017–FY2020 research project, the company is developing a low-cost automated system for large-scale passaging culture based on CellPet 3D-iPS, meeting requirements for quality, variability and cost.